What is nephritic factor activity?
Nephritic factors The typical nephritic factor is an IgG autoantibody that binds to the alternative pathway convertase called C3bBb. Nephritic factor stabilizes and prolongs the activity of the enzyme by interfering with normal factors controlling the convertase activity.
What is C3 glomerulonephritis?
C3 glomerulonephritis (C3GN) is a recently described entity that shows a glomerulonephritis on light microscopy (LM), bright C3 staining and the absence of C1q, C4 and immunoglobulins (Ig) on immunofluorescence microscopy (IF), and mesangial and/or subendothelial electron dense deposits on electron microscopy (EM).
What is C3 in kidney biopsy?
C3G stands for complement 3 glomerulopathy. The “C3” refers to a blood protein that plays a key role in normal immunity and in the development of this disease. More on this later. The “G” is for glomerulopathy, meaning damage to the glomeruli in the kidney.
What is C3 disease?
Complement 3 glomerulopathy (C3G) is a rare kidney disease that has two forms: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). Each is caused by genetic or acquired problems in controlling the body’s complement system, which helps fight infections. Genetic problems can be inherited or not inherited.
What is dense deposit disease?
Dense deposit disease (DDD), also called membranoproliferative glomerulonephritis type II or MPGN II, is a rare autoimmune disease that affects the kidneys and the eyes. As the name MPGN II implies, DDD damages the glomeruli within the kidneys.
What is a dense kidney?
Proteins that are part of the immune system attack and stick to the glomerular basement membrane in thick patches that are called dense deposits. Over time, these deposits interfere with the kidneys’ ability to filter fluids and wastes from the blood.
What does it mean if your C3 is low?
If only your C3 complement level is low and all other complement components are normal, it’s usually because of an inherited component deficiency. This makes it more likely that you will develop certain autoimmune disorders. More often, you will have low levels of several complement components at once.
How rare is dense deposit disease?
Dense deposit disease (DDD; also known as membranoproliferative glomerulonephritis type II) is a prototypical rare disease. It affects only two to three people per million and leads to renal failure within 10 yr in 50% of affected children.
Is C3 convertase C4b2a or c4b2b?
C3 convertase can be used to refer to the form produced in the alternative pathway (C3bBb) or the classical and lectin pathways (C4bC2b, formerly C4b2a).
What complement components make up C3 convertase and what does it do?
C3: The Key Complement Component When C3 convertase converts inactive C3 molecules, two active components, C3a and C3b, are produced, with C3b binding covalently to the surface of pathogens, cells or other surfaces.
What is the function of complement component 3?
Complement component 3. Complement component 3, often simply called C3, is a protein of the immune system. It plays a central role in the complement system and contributes to innate immunity. In humans it is encoded on chromosome 19 by a gene called C3.
How is C3 cleaved in the alternative complement pathway?
In the alternative complement pathway, C3 is cleaved by C3bBb, another form of C3-convertase composed of activated forms of C3 (C3b) and factor B (Bb). Once C3 is activated to C3b, it exposes a reactive thioester that allows the peptide to covalently attach to any surface that can provide a nucleophile such as a primary amine or a hydroxyl group.
What are the electron-dense deposits in DDD and c3gn?
Sophisticated studies have been done to determine the precise composition of the electron-dense deposits in DDD and C3GN, and in addition to C3 the glomeruli contain many other proteins that belong to a system called the complement system. Proteins from both the alternative pathway of complement and the terminal pathway of the complement are found.
Can complement biomarkers help drive treatment decisions in patients with C3G?
Because the treatment of C3G is difficult, it is hoped that this type of information may provide clinicians with insight into what is happening at the level of the complement system in their patients with DDD and C3GN. One day, complement biomarker profiling may also help drive treatment decisions.